GAMMA Investing LLC increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 50,249.4% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 121,342 shares of the company's stock after purchasing an additional 121,101 shares during the quarter. GAMMA Investing LLC owned approximately 0.42% of Krystal Biotech worth $21,878,000 at the end of the most recent reporting period.
Other large investors have also recently added to or reduced their stakes in the company. US Bancorp DE raised its position in shares of Krystal Biotech by 8.7% in the fourth quarter. US Bancorp DE now owns 1,027 shares of the company's stock valued at $161,000 after purchasing an additional 82 shares during the period. Summit Investment Advisors Inc. grew its stake in Krystal Biotech by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after buying an additional 82 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in Krystal Biotech by 1.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock worth $1,822,000 after acquiring an additional 121 shares during the period. Xponance Inc. lifted its position in Krystal Biotech by 9.5% during the 4th quarter. Xponance Inc. now owns 1,785 shares of the company's stock worth $280,000 after acquiring an additional 155 shares during the last quarter. Finally, Bank of Montreal Can lifted its position in Krystal Biotech by 5.7% during the 4th quarter. Bank of Montreal Can now owns 3,325 shares of the company's stock worth $521,000 after acquiring an additional 179 shares during the last quarter. Institutional investors own 86.29% of the company's stock.
Insiders Place Their Bets
In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now directly owns 1,463,711 shares of the company's stock, valued at approximately $260,233,178.69. This represents a 1.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 13.70% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $240.00 price objective on shares of Krystal Biotech in a research note on Tuesday, May 6th. Citigroup lowered their target price on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a report on Friday, May 16th. Jefferies Financial Group began coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price target on the stock. Guggenheim reduced their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Finally, Chardan Capital restated a "buy" rating and issued a $219.00 price objective on shares of Krystal Biotech in a research note on Wednesday, May 7th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $211.13.
Read Our Latest Stock Report on KRYS
Krystal Biotech Stock Performance
Shares of NASDAQ:KRYS traded up $4.32 during trading on Friday, hitting $136.94. 265,790 shares of the stock were exchanged, compared to its average volume of 311,528. The company has a market capitalization of $3.96 billion, a price-to-earnings ratio of 45.80 and a beta of 0.65. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $219.34. The company's fifty day simple moving average is $149.85 and its 200-day simple moving average is $163.23.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing analysts' consensus estimates of $1.38 by ($0.18). Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. On average, research analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.
About Krystal Biotech
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Stories
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
